Senti Biosciences, Inc.

Equities

SNTI

US81726A1007

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
0.2809 ^USD	-6.37%		-9.39%	-57.44%

Mar. 21	Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 21	Earnings Flash (SNTI) SENTI BIOSCIENCES Reports 2023 Revenue $2.6M	MT

Senti Biosciences, Inc. Auditor Raises 'Going Concern' Doubt

April 31, 2022

Senti Biosciences, Inc. filed its S-4/A on Apr 01, 2022 for the period ending Dec 31, 2021. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Senti Biosciences, Inc.

Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Earnings Flash (SNTI) SENTI BIOSCIENCES Reports 2023 Revenue $2.6M	Mar. 21	MT
Senti Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Spark Therapeutics, Inc. Announces Workforce Reduction	Jan. 05	CI
Top Premarket Gainers	Dec. 22	MT
Senti Biosciences, Inc. Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	Dec. 22	CI
Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Earnings Flash (SNTI) SENTI BIOSCIENCES Posts Q3 Revenue $338,000	Nov. 13	MT
Senti Biosciences, Inc. Announces New Strategic Collaboration with Celest Therapeutics Co. Ltd	Nov. 06	CI
Earnings Flash (SNTI) SENTI BIOSCIENCES Posts Q2 Revenue $937,000	23-08-11	MT
Senti Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Senti Biosciences, Inc. Announces Resignation of Philip Lee as Chief Technology Officer	23-08-10	CI
GeneFab, LLC acquired Rights, title and interest in certain of the assets from Senti Biosciences, Inc. for $37.8 million.	23-08-09	CI
Senti Biosciences, Inc. Highlights Initial Gene Circuit Data from Collaborations At the American Society of Gene and Cell Therapy Annual Meeting	23-05-20	CI
Chardan Cuts Price Target on Senti Biosciences to $6 From $7, Keeps Buy Rating	23-05-11	MT
Earnings Flash (SNTI) SENTI BIOSCIENCES Posts Q1 Revenue $1.3M	23-05-09	MT
Senti Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Senti Biosciences, Inc. Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs At Annual American Association for Cancer Research Meeting	23-04-17	CI
Morgan Stanley Adjusts Price Target on Senti Biosciences to $2 From $3, Keeps Equalweight Rating	23-03-24	MT
Chardan Adjusts Price Target on Senti Biosciences to $7 From $8, Keeps Buy Rating	23-03-23	MT
Earnings Flash (SNTI) SENTI BIOSCIENCES Reports Q4 Revenue $59,000	23-03-22	MT
Senti Biosciences, Inc. Announces Strategic Plan to Focus Research and Development Efforts on Lead Oncology Candidate SENTI-202	23-03-22	CI
Senti Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	23-03-21	CI
Senti Biosciences, Inc. Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting	23-03-14	CI
Chardan Adjusts Senti Biosciences' Price Target to $8 From $12, Keeps Buy Rating	23-01-30	MT

Chart Senti Biosciences, Inc.

Duration

Period

More charts

Company Profile

Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
SENTI BIOSCIENCES, INC.	-57.44%	13.73M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	105B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.53%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.09%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	14.09B
SAREPTA THERAPEUTICS, INC.	+28.85%	10.99B

Bio Therapeutic Drugs